Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CPI-818 |
Synonyms | |
Therapy Description |
CPI-818 inhibits IL-2 inducible T-cell kinase (ITK), which may lead to inhibition of TCR signaling and growth of T cells (Cancer Res 2019;79(13 Suppl):Abstract nr 1313). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CPI-818 | CPI818|CPI 818 | CPI-818 inhibits IL-2 inducible T-cell kinase (ITK), which may lead to inhibition of TCR signaling and growth of T cells (Cancer Res 2019;79(13 Suppl):Abstract nr 1313). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03952078 | Phase I | CPI-818 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | Recruiting | USA | 3 |